Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ureteral Jets on Cystoscopy

NCT02476448
View directory record Official record
Conditions
Injury of Ureter
Interventions
Normal saline, Phenazopyridine, Dextrose 10%, Sodium Fluorescein
Drug
Lead sponsor
Cecilia Calvo
Other
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

NCT02377414
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban solution for Infusion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Can PLIA Reduce Early Post-operative Pain After PAO Surgery?

NCT06519955
View directory record Official record
Conditions
Hip Dysplasia
Interventions
Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
13 Years to 50 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 17, 2026, 6:29 PM EDT
Recruiting Not applicable Interventional

Physical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI)

NCT05458947
View directory record Official record
Conditions
Spinal Cord Injuries, Pressure Injuries
Interventions
pulsed wound irrigation (PWI), electrical stimulation (ES), electrical stimulation (ES) and pulsed wound irrigation (PWI)
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19

NCT04723563
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
Heparin, 0.9%sodium chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

Corticosteroids to Treat Pancreatitis

NCT05160506
View directory record Official record
Conditions
Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

NCT04385849
View directory record Official record
Conditions
COVID-19
Interventions
N-803, Saline
Biological · Other
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 17, 2026, 6:29 PM EDT
Terminated Phase 3 Interventional Results available

ARrest RESpiraTory Failure From PNEUMONIA

NCT04193878
View directory record Official record
Conditions
Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Interventions
Inhaled budesonide and formoterol, Inhaled placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin Effects on Plantar Ulcer Recurrence

NCT00845897
View directory record Official record
Conditions
Diabetes Mellitus, Peripheral Neuropathy, Plantar Ulcers
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT01005888
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

NCT02004691
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
placebo (saline), Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
San Francisco, California • Decatur, Georgia • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
View directory record Official record
Conditions
Endocrine Tumors
Interventions
lanreotide (Autogel formulation), Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of ECO Conversion System For Red Blood Cells.

NCT00261274
View directory record Official record
Conditions
Anemia
Interventions
A-ECO, Saline
Biological
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 17, 2026, 6:29 PM EDT
Terminated Phase 3 Interventional Results available

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

NCT04607668
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
Interventions
Trilaciclib, Placebo
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age

NCT05630859
View directory record Official record
Conditions
Sexually Transmitted Diseases
Interventions
NgG 12.5 µg investigational vaccine, NgG 25 µg investigational vaccine, NgG 50 µg investigational vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,009 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Terminated Not applicable Interventional Results available

Post-op Treatment With Hyaluronic Acid Injections

NCT01256788
View directory record Official record
Conditions
Meniscus Tear, Chondropathy/Degenerative Joint Disease (DJD)
Interventions
Euflexxa, Saline
Device · Other
Lead sponsor
The Hawkins Foundation
Other
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

NCT00822523
View directory record Official record
Conditions
Muscle Strength, Botulinum Toxins, Type A
Interventions
Botulinum Toxin, Type A, Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 54 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 17, 2026, 6:29 PM EDT
Recruiting Not applicable Interventional

H. Pylori Eradication With Argon Plasma During Endoscopy

NCT06529159
View directory record Official record
Conditions
Helicobacter Pylori Infection, Helicobacter Pylori, Helicobacter Pylori Gastrointestinal Tract Infection, H. Pylori Infection, H. Pylori Gastrointestinal Disease
Interventions
HEAPE, Pre-HEAPE
Procedure
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 17, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 17, 2026, 6:29 PM EDT